AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site

AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.

Related Keywords

Puerto Rico ,Singapore ,Tuas ,Singapore General ,United States ,America ,Azita Saleki Gerhardt ,Cindy Koh ,Yoosook Kim ,John Torrisi ,Youtube ,Twitter ,Linkedin ,Facebook ,Instagram ,Singapore Economic Development Board ,Tuas Biomedical Park ,Abbvie Executive Vice President ,Chief Operations ,Executive Vice President ,Singapore Economic Development ,Allergan Aesthetics ,Abbvie ,Government Of Singapore ,Lobal Manufacturing Network ,